在治疗tebentafusp期间瘤免疫格局的演变,tebentafusp是一种T细胞受体-CD3双特异的T细胞受体
Joseph J Sacco1, Peter Kirk2, Emma Leach2
1Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, UK; University of Liverpool, Liverpool, UK.
Cell reports. Medicine
|April 16, 2025
概括
基于T细胞受体 (TCR) 的CD3双特异性疗法Tebentafusp对转移性乳膜黑色素瘤具有临床益处. 治疗前的干扰素基因表达和持久的瘤微环境变化预测了更好的生存率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 转移性阴道黑色素瘤是一种具有有限治疗选择的侵袭性癌症.
- 这种癌症通常对传统的免疫检查点抑制剂具有抗性.
- 基于T细胞受体 (TCR) 的新型CD3双特异抗体Tebentafusp提供了临床益处.
研究的目的:
- 为了阐明tebentafusp在转移性紫外线黑色素瘤中的有效性背后的分子机制.
- 为了确定tebentafusp治疗反应的预测生物标志物.
- 探索CD3双特异性治疗在固体瘤中的潜在新疗法.
主要方法:
- 分析不同时间点 (治疗前,治疗初期,进展) 用tebentafusp (NCT02570308) 治疗的患者的瘤活检.
- 利用RNA测序 (RNA-seq) 和免疫组织化学 (IHC) 进行分子分析.
- 与临床结果相关的分子数据,如总体存活率和瘤减少.
主要成果:
- 在治疗前对干扰素相关基因的升级与改善的整体存活率和瘤反应有关.
- Tebentafusp有效地将T细胞招募到瘤微环境中,即使在初始T细胞透率低的瘤中也是如此.
- 瘤微环境中tebentafusp诱导的变化的持久性对于持续的患者存活至关重要.
结论:
- 干扰素通路激活是转移性阴道黑色素瘤中对tebentafusp反应的关键预测因子.
- 泰班塔法斯普表现出强大的T细胞参与活性,克服了低基线T细胞透.
- 通过tebentafusp对瘤微环境的持续调节对于长期的临床益处至关重要.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
404
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
404
02:17The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
02:07Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K